In hepatocellular carcinoma, aberrant activation of the PI3K/AKT/mTOR pathway—often due to PIK3CA mutations—is closely associated with aggressive tumor behavior and poor clinical outcomes. This evidence concerns the gene AKT1 and neoplasm.